What Could Derail The Biotech Rally?

On?episode 186?of the Business of Biotech, Allan Shaw references how politicians like to pick on pharma and biotech, particularly during an election year. God help you if you’re a?multinational?biotech doing business here.

This month, some legislators in Washington (who claim they don’t particularly care for the geopolitical games the Chinese government plays, but who continue to engage in said games, seemingly for the sport of it) decided to make Chinese biotech the object of their ire. Apparently, they consider therapeutic innovation the latest of China’s exports to pose a risk to America.

How ‘bout we focus on all that spy stuff first? Or maybe get back to letting something entirely useless get under our skin, like TikTok?

Here’s a roundup of the month’s best Life Science Connect fodder for Business of Biotechers, and some highlights from another month of podcasting our way around the country. Enjoy! Share! Subscribe!

Thanks for listening,

Matthew Pillar , Business of Biotech host and chief editor, Bioprocess Online

Biotech Beat

Novo/Catalent: The Insider’s Take

The 诺和诺德 / Catalent Pharma Solutions deal has been covered in nauseating fashion. No one has covered it as well as our man on the scene, Louis Garguilo over at Outsourced Pharma . He’s actually talked with Novo and Catalent execs and employees. Start with his day-of column above, then hit his follow-ups?here?and?here. I’m sure there’s more to come. READ NOW →

The Biotech CEO’s Inherent Conflict

My colleague, Ben Comer , dug deep into the evolution of the biotech Dynavax Technologies in this interview with controller-turned-CEO Ryan Spencer . This is requisite, 500-level material for any leader who wants to master the damn-near impossible: managing the conflict between “saving the world with innovation” and “sound financial management against a revenue stream.” READ NOW →

AI’s “Pick Me” Moment

After the dozen podcasts we recorded in San Francisco were time-stamped, edited (sort of), and queued up, I got around to drafting up some reflections on last month’s J.P. Morgan Healthcare Conference. Tried to avoid the stuff that gets pounded over our heads in the news cycles and hit a few of the nuanced undertones, like AI and platforms becoming defacto standards of biotech. READ NOW →

Peter Marks On Cell & Gene Live

My buddy Erin Harris landed Dr. Peter Marks, Director, CBER, FDA and Dr. Nicole Verdun , Super Office Director, CBER, FDA for an hour of live-broadcast questioning last month. She set a new standard for live event audience acquisition by attracting a bazillion biotech SMES, and while the Q&A period is now closed, you can catch it on demand right here at Cell & Gene .

VIEW ON-DEMAND →

Quotes Of The Month

“When we do make a decision [to sunset a program], yes, certain individuals and certain project team members will be disappointed. But we get over that, we move on.”

― Jim Lee , M.D., Ph.D., group VP and head of Inflammation and AutoImmunity, Incyte ,?Episode 185

“It's the platitudes. It’s the tweets. Pharma and biotech seem to be the politicians’ favorite whipping boy, which is kind of ironic when you think about the contribution and impact we’ve made.”

― Allan Shaw ,?Episode 186

"Competition is great for the field. I mean, it's fantastic. The more approaches we see, the better we get, and there are so many diseases that can be potentially treated with mRNA.”

― Carsten Rudolph, Dr. , Ph.D., co-founder and CEO, Ethris ,?Episode 187

Advancing RNA | Bioprocess Online | Cell & Gene | Clinical Leader | Drug Delivery | Life Science Leader | Pharmaceutical Online | Outsourced Pharma

? Copyright 2024 Vertmarkets, Inc. 5340 Fryling Rd Suite 100, Erie, PA 16510